Telix Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals for oncology. Leveraging a pipeline of molecularly targeted radioisotope products, Telix seeks to improve the accuracy of cancer imaging and expand treatment options for patients with hard-to-treat tumors. The company’s core expertise lies in harnessing medical isotopes to deliver precision diagnostics and targeted radiotherapy, addressing conditions such as prostate, kidney and brain cancers.
Among its key offerings is Illuccix®, a kit for the preparation of gallium-68 prostate-specific membrane antigen (PSMA) PET imaging, which has been approved in multiple jurisdictions for the detection and management of prostate cancer. In parallel, Telix is advancing TLX250-CDx, a zirconium-89–labeled agent designed to support the noninvasive characterization of renal cell carcinoma. On the therapeutic side, the company’s investigational product TLX101 uses iodine-131 to target glioblastoma multiforme, while other candidates in development pair lutetium-177 or actinium-225 with tumor-targeting ligands to address prostate and other solid tumors.
Founded in 2015 as a spin-out from Australia’s national science agency, Telix has since established a global footprint with corporate headquarters in Melbourne and operational centers in North America, Europe and Asia. The company collaborates with leading nuclear medicine institutions, isotope suppliers and contract manufacturers to ensure a robust supply chain and expedite clinical development. Telix has secured regulatory approvals and breakthrough designations in key markets, underscoring its commitment to delivering radiopharmaceutical innovation to physicians and patients worldwide.
Under the leadership of Chief Executive Officer Dr. David Gilham, Telix has assembled a management team with extensive experience in oncology drug development, nuclear medicine and commercial operations. The board includes industry veterans and scientific advisors who guide the company’s strategic direction and clinical priorities. With a focus on expanding its product portfolio and forging partnerships, Telix aims to become a leader in the emerging field of targeted radiopharmaceuticals for cancer care.
AI Generated. May Contain Errors.
Free TLX Stock Alerts